Swallowable Capsule Electrical Stimulation for Incretin Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and obesity, such as insulin injections and drug therapies, are inefficient and often lead to complications, while existing drug therapies for obesity fail to effectively stimulate satiety signals, and there is a need for improved methods to regulate glucose levels and suppress appetite.
Innovation Solution
A swallowable capsule with electrodes and sensors is used to electrically stimulate L-cells in the small intestine to secrete glucagon-like peptides (GLP-1) and other incretins, coordinating insulin production with nutrient absorption to manage blood glucose levels and appetite.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If electrical stimulation is applied to stimulate L-cells to secrete incretins, then incretin production is improved, but peristaltic contractions may be caused which could interfere with capsule positioning
Solution Approach 1:
The patent applies different electrical stimulation parameters to different locations and cell types within the intestinal tract. By controlling the frequency, amplitude, and duration of electrical pulses, the system selectively stimulates L-cells to secrete incretins while avoiding the activation of peristaltic muscle contractions. This localized control of electrical stimulus characteristics enables differentiation between desired cellular response and unwanted mechanical response.
Solution Approach 2:
The system dynamically adjusts electrical stimulation parameters including pulse frequency, voltage amplitude, and duty cycle to optimize incretin secretion while minimizing peristaltic activity. By changing these physical parameters of the electrical stimulus, the system can target specific cellular responses (incretin release from L-cells) without triggering broader physiological responses (peristaltic contractions) that would disrupt capsule positioning.
2Ease of operation
If drug therapies are used to treat obesity, then appetite suppression is attempted, but the therapies fail to effectively stimulate satiety signals
Solution Approach 1:
The patent replaces chemical drug therapy with an electrical stimulation mechanism to stimulate satiety signals. Instead of using pharmaceutical agents that fail to reliably activate satiety pathways, the system uses controlled electrical pulses to directly stimulate L-cells in the intestinal tract to secrete incretins, which are natural hormones that regulate appetite and promote satiety. This substitution of electrical stimulus for chemical stimulus provides more reliable and controllable activation of satiety signals.
Solution Approach 2:
The system uses incretin hormones as intermediaries between the electrical stimulation and the satiety signal pathway. The electrical stimulus does not directly suppress appetite but rather triggers L-cells to release incretins, which then act as chemical messengers to signal satiety to the brain. This intermediary approach ensures reliable activation of the body's natural appetite regulation system rather than attempting direct pharmacological suppression.
3Reliability
If insulin injections are administered, then blood glucose control is achieved, but the treatment is inefficient and leads to complications
Solution Approach 1:
Instead of directly administering insulin to control blood glucose, the patent inverts the approach by stimulating the body's own insulin production. The electrical stimulation of L-cells to secrete incretins triggers a physiological cascade that naturally leads to increased insulin secretion from pancreatic beta-cells in response to nutrient absorption. This indirect approach mirrors the body's natural glucose regulation mechanism rather than bypassing it with exogenous insulin administration.
Solution Approach 2:
The system enables the body's own endocrine system to perform glucose regulation without external insulin injections. By stimulating intestinal L-cells to release incretins, the treatment activates the body's intrinsic glucose-insulin regulatory pathway, allowing pancreatic cells to self-regulate glucose levels in response to nutrient presence. This self-service approach eliminates the need for external insulin administration and its associated complications while maintaining effective glucose control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The capsule effectively stimulates incretin secretion to regulate insulin levels and appetite, providing improved glucose control and weight management without causing peristaltic contractions, and can be adapted for patients with slow intestinal transit.
Implementation Method 1
electrically stimulate L-cells in the small intestine to secrete glucagon-like peptides (GLP-1) and other incretins
Data Source
AI summary
Embodiments of the invention provide apparatus and methods for stimulating L cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating L-cells to secrete incretins to stimulate or otherwise modulate the production of insulin. Particular embodiments provide a swallowable capsule for stimulating L-cells in the intestinal tract as the capsule moves through the tract. The capsule can include two or more electrodes for providing electrical stimulation to L-cells, a power source for powering one or more components of the capsule, a sensor for sensing the location of the capsule in the intestinal tract; a controller and a waveform generator for generating the electrical signals emitted by the electrodes to stimulate the L-cells to secrete incretins such as GLP-1 to stimulate insulin production for glucose regulation of diabetic conditions.